An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion.

Unlabelled: This study includes over 11.6M newborns screened (NBS) for Pompe Disease (PD) from 29 distinct universal screening programs across 8 countries and 4 continents. The birth prevalence of PD is 1:18,711, with no evidence of difference across populations of European, Latin American, or Asian ancestry, though differences may exist for PD subtypes.

Subcutaneous and intramuscular administration of a SARS-CoV-2 vaccine are similarly effective in generating a humoral response in domestic goats (Capra hircus).

Objective: To determine severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) serum antibody titers in domestic goats after SC and IM administration of an experimental, veterinary SARS-CoV-2 vaccine.

Animals: 31 healthy adult domestic goats from 4 zoological institutions.

Methods: On day 0, blood was collected for baseline serum titer before vaccination with 1 mL SARS-CoV-2 recombinant S protein vaccine SC (n = 22) or IM (n = 9).

Atypical Brucella inopinata-Like Species in 2 Marine Toads.

We describe the isolation of atypical Brucella inopinata-like species and unique clinicopathologic findings in 2 adult marine toads (Rhinella marina), including oophoritis in 1 toad. These findings represent a novel emerging disease in toads and a possible zoonotic pathogen.

Discovery and optimization of a novel series of pyrazolyltetrahydropyran N-type calcium channel (Ca 2.2) blockers for the treatment of pain.

A novel series of pyrazolyltetrahydropyran N-type calcium channel blockers are described. Structural modifications of the series led to potent compounds in both a cell-based fluorescent calcium influx assay and a patch clamp electrophysiology assay. Representative compounds from the series were bioavailable and showed efficacy in the rat CFA and CCI models of inflammatory and neuropathic pain.

The antibody rHIgM22 facilitates hippocampal remyelination and ameliorates memory deficits in the cuprizone mouse model of demyelination.

Multiple sclerosis (MS) is a chronic, inflammatory demyelinating disease of the CNS. In addition to motor, sensory and visual deficits, MS is also characterized by hippocampal demyelination and memory impairment. We recently demonstrated that a recombinant human-derived monoclonal IgM antibody, which is designated rHIgM22 and currently in clinical development for people with MS, accelerates remyelination of the corpus callosum in the brains of cuprizone-treated mice.